16 Hrs
Source:
Sharjah24
Source: Sharjah24
16 HrsSharjah24
Source: Sharjah24
16 HrsReady to play
Ready to play
A clinical trial demonstrated that the new drug "Aikotrakinra" produced by Johnson & Johnson, exclusively known as "Aikotaid," significantly outperformed the placebo in treating ulcerative colitis. The study included 252 patients with moderate to severe disease, who received daily doses ranging from 100 to 400 milligrams. Results showed that the clinical response rate ranged between 55% and 63%, depending on the dose, compared to 27% in the placebo group. Additionally, the highest remission rates and improved endoscopic outcomes were observed with the 400-milligram dose, with sustained clinical remission and symptom reduction throughout the 28-week treatment period. These findings indicate that the drug demonstrated clear efficacy, even in patients who had previously failed other treatments. Further research is expected to explore its potential impact on Crohn's disease.
Notice: This Is an AI-Generated Summary
Comments (0)